Comparative Evaluation of the Effects of 5-Aza-2'-deoxycytidine and Trichostatin A on Reactivation of hMLH1 in COC1/DDP Ovarian Cancer Cell Line

被引:0
|
作者
Chun-feng Meng1
机构
关键词
Ovarian cancer; DNA methylation; Drug resistance; hMLH1; 5-Aza-2’-deoxycytidine; Trichostatin A;
D O I
暂无
中图分类号
R737.31 [卵巢肿瘤];
学科分类号
100214 ;
摘要
Objective:hMLH1 protein serves to detect the DNA damage caused by cisplatin(DDP) and destroys the cell.The absence of hMLH1 expression has been correlated with acquired resistance of ovarian cancer cells to platinum.The aim of this study was to determine the possible role of DNA methylation and histone H3 lysine 9(H3-K9) acetylation on the loss of hMLH1 expression,and to evaluate the reversal effects of 5-Aza-2’-deoxycytidine(5-Aza-dC) and Trichostatin A(TSA) on DDP-resistance in ovarian cancer cell lines.Methods:Two human ovarian cancer cell lines,COC1 and its DDP-resistant subline,COC1/DDP were cultured.The two cancer cells were treated with 5-Aza-dC or TSA.Using COC1 cells as a control,we used methylation-specific PCR(MSP) to analyze DNA methylation at hMLH1 gene promoter.hMLH1 mRNA and protein expressions were analyzed by reverse transcriptase-polymerase chain reaction(RT-PCR) and Western blot.Chromatin immunoprecipitation assay(ChIP) was used to test the levels of histone H3-K9 acetylation at hMLH1 gene promoter.Results:In COC1 cells,there was no DNA methylation at hMLH1 gene promoter,while there were hMLH1 mRNA and protein expression.In COC1/DDP cells,there was DNA hypermethylation at hMLH1 gene promoter,while there was no hMLH1 mRNA or protein expression.The treatment with 5-Aza-dC resulted in DNA demethylation at the promoter region,as well as restoration of hMLH1 expression in COC1/DDP cells.The treatment with TSA had no effects on DNA demethylation or restoration of hMLH1 expression in COC1/DDP cells.Conclusion:Hypermethylation of DNA at the promoter is related to the silencing of hMLH1 in COC1/DDP ovarian cancer cells.DNA methylation at hMLH1 promoter could play a significant role in determining the sensitivity of ovarian cancer to DDP.The drug resistance mediated by methylation of hMLH1 could be overcome by 5-Aza-dC.
引用
收藏
页码:102 / 108
页数:7
相关论文
共 50 条
  • [31] The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2′deoxycytidine (decitabine) are differentially regulated by cell cycle progression
    Al-Salihi, Mazin
    Yu, Margaret
    Burnett, David M.
    Alexander, Amanda
    Samlowski, Wolfram
    Fitzpatrick, F. A.
    EPIGENETICS, 2011, 6 (08) : 1021 - 1028
  • [32] 5-aza-2′-deoxycytidine reactivates the CDH1 gene without influencing methylation of the entire CpG island or histone modification in a human cancer cell line
    Tachibana, K
    Takeda, K
    Shiraishi, M
    PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES, 2004, 80 (07): : 342 - 348
  • [33] Effect of combined therapy with low dose 5-Aza-2′-deoxycytidine and irinotecan on colorectal cancer cell line HCT-15
    Ishiguro, M
    Iida, S
    Uetake, H
    Morita, S
    Makino, H
    Kato, K
    Takagi, Y
    Enomoto, M
    Sugihara, K
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (02) : 57 - 57
  • [35] Retraction Note to: Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2'-deoxycytidine
    Chien-Chung CHANG
    Cell Research, 2005, 15 (8) : 678 - 678
  • [36] Differential sensitization of two human colon cancer cell lines to the antitumor effects of irinotecan combined with 5-aza-2'-deoxycytidine
    Hakata, Shuko
    Terashima, Jun
    Shimoyama, Yu
    Okada, Kouji
    Fujioka, Shiho
    Ito, Erika
    Habano, Wataru
    Ozawa, Shogo
    ONCOLOGY LETTERS, 2018, 15 (04) : 4641 - 4648
  • [37] Trichostatin A and 5-aza-2′-deoxycytidine switch S1P from an inhibitor to a stimulator of motility through epigenetic regulation of S1P receptors
    Koh, Eunjin
    Bandle, Russell
    Clair, Timothy
    Roberts, David D.
    Stracke, Mary L.
    CANCER LETTERS, 2007, 250 (01) : 53 - 62
  • [38] Re-expression of hMLH1 in vivo by the demethylating agent 5-aza-2-deoxycytidine sensitises a mismatch repair deficient ovarian tumour xenograft to cisplatin, temozolomide and epirubicin.
    Plumb, JA
    Sludden, J
    Strathdee, G
    Brown, R
    CLINICAL CANCER RESEARCH, 1999, 5 : 3851S - 3851S
  • [39] Effect of 5′-fluoro-2′-deoxycytidine, 5-azacytidine, and 5-aza-2′-deoxycytidine on DNA Methyltransferase 1, CIP/KIP Family, and INK4a/ARF in Colon Cancer HCT-116 Cell Line
    Sanaei, Masumeh
    Kavoosi, Fraidoon
    INTERNATIONAL JOURNAL OF CANCER MANAGEMENT, 2021, 14 (12)
  • [40] hMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors
    Colella, G
    Vikhanskaya, F
    Codegoni, AM
    Bonazzi, C
    D'Incalci, M
    Broggini, M
    CARCINOGENESIS, 1998, 19 (04) : 691 - 694